




## Camurus' Capital Markets and R&D Day Program

14 DECEMBER 2016

A blurred background image of laboratory glassware, including a large Erlenmeyer flask in the foreground and several test tubes in the background, all set against a blue and white bokeh light effect.

**Venue:** Wallenbergsalen,  
Kungliga Ingenjörsvetenskapsakademien, IVA  
Grev Turegatan 16, Stockholm

**Invitation for:** Institutional investors, analysts and media  
To participate, please register no later than  
9 December at [CMD@camurus.com](mailto:CMD@camurus.com)

**Moderator:** Lars Frick, Börsveckan



## Agenda

Time	Topic	Presenter
13:00 – 13:30	Registration and coffee	
13:30 – 14.45	Welcome and introduction	<i>Fredrik Tiberg, CEO and Head R&amp;D Rein Piir, VP IR</i>
	The FluidCrystal® technology	<i>Markus Johnsson, VP Pharm. Dev.</i>
	Weekly and monthly buprenorphine depots (CAM2038): Overview and clinical development update	<i>Peter Hjelmström, Senior Director Medical Affairs Fredrik Tiberg, CEO and Head R&amp;D</i>
	Clinician’s view on long-acting depots for opioid use disorder – a potential new treatment paradigm	<i>Edward Nunes, MD, Professor of Psychiatry at Columbia University Medical Center</i>
14:45 – 15.00	Q&A	
15:00 – 15:20	Refreshments	
15:20 – 16:45	CAM2038: US market perspectives	<i>Behshad Sheldon, CEO Braeburn Pharmaceuticals</i>
	CAM2038: EU market perspectives and commercialisation	<i>Richard Jameson, CCO</i>
	Advancing the pipeline: Late and early stage projects update	<i>Fredrik Tiberg, CEO and Head R&amp;D Markus Johnsson, VP Pharm. Dev.</i>
16:45 – 17:00	Conclusions and Q&A	

**About Camurus** Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit [www.camurus.com](http://www.camurus.com)

## Presenters' biographies

### **Fredrik Tiberg, Chief Executive Officer and Head R&D Camurus**

Fredrik Tiberg serves as President and Chief Executive Officer of Camurus. Prior to assuming this role in 2003, he was Vice President, Head of R&D. He also holds a position as Adjunct Professor of Surface and Colloid Chemistry at Lund University, and is a member of the Royal Swedish Academy of Engineering Sciences (IVA). Fredrik was appointed Associate Professor in Physical Chemistry in 1998 and Professor in 1999. During 2001-2002 he was Visiting Professor at the Physical and Theoretical Chemistry Laboratory, Oxford University, and Special Supernumerary Fellow of University College.

### **Rein Piir, Vice President Investor Relations Camurus**

Rein Piir has many years of experience as advisor to listed companies, including as head of research at Carnegie Investment Bank AB and strategist at Alecta. He was 14 years as CFO/Head of Investor Relations at Medivir AB, and three years as an auditor at PricewaterhouseCoopers AB. Rein holds a M.Sc. in Business Administration from Uppsala University.

### **Markus Johnsson, Vice President Pharmaceutical Development Camurus**

Markus Johnsson holds a Ph.D. in physical chemistry and M.Sc. in chemistry from Uppsala University. Prior to joining Camurus he was a postdoctoral researcher at the University of Groningen and a Senior Scientist at Uppsala University.

### **Peter Hjelmström, Senior Director Medical Affairs**

Peter Hjelmström holds M.D. and Ph.D. degrees and is associate professor from Karolinska Institutet. He has worked over 10 years in the pharmaceutical industry and prior to joining Camurus he held positions at Alexion as Medical Affairs Manager, Orexo as Chief Medical Officer, Swedish Orphan Biovitrum as Head of Clinical Science and Serono International as Senior Scientific Advisor. Peter also did a postdoctoral fellowship at Yale University School of Medicine, USA.

### **Edward Nunes, MD, Professor of Psychiatry at Columbia University Medical Center**

Edward Nunes is a Professor of Psychiatry, and Principal Investigator of the Greater New York Node of the National Drug Abuse Clinical Trials Network (funded by NIDA). Interests and ongoing studies include treatments for cocaine and other stimulant dependence, heroin and other opioid dependence, nicotine dependence, and treatments for addicted patients with co-occurring psychiatric disorders including depression, post-traumatic stress disorder and attention deficit disorder. Edward also served on the American Board of Addiction Medicine, is Co-Chairman of the Columbia/New York State Psychiatric Institute's Institutional Review Board, and has been appointed to the National Advisory Council on Drug Abuse.

### **Behshad Sheldon, Chief Executive Officer Braeburn Pharmaceuticals**

Behshad Sheldon has more than 25 years of experience leading pharmaceutical development and commercialization in the United States and globally. Prior to joining Braeburn, Behshad spent 10 years at Otsuka Pharmaceuticals, having co-founded the Otsuka Princeton office in 2002. Ms. Sheldon last served as a member of the board of directors of the Otsuka R&D organization, contributing to the oversight of 18 pre-approval programs for 13 products in CNS, cardio-renal, pain, dermatology, and oncology. Simultaneously, she served as senior vice president, patient & branding strategy in the commercial organization, where she was responsible for global and United States marketing, alliance management, and early development strategy. Prior to Otsuka, Behshad held positions with increasing responsibility at SmithKline Beecham and Bristol-Myers Squibb. Throughout her 27-year career, Behshad has driven the success of blockbuster products such as Glucophage, Plavix, and Abilify, and has contributed to several strategic alliances and acquisitions, including the landmark 2011 agreement between Otsuka and Lundbeck involving 5 CNS products. Behshad holds a BS degree in Neuroscience from the University of Rochester.

### **Richard Jameson, Chief Commercial Officer Camurus**

Richard Jameson has many years of experience in the speciality pharmaceutical industry including senior positions in sales leadership, marketing, market access and general management for companies which include Serono, Schering Plough, Ferring and Indivior PLC. He holds a B.Sc. (Hons) in Applied Biological Sciences from University West of England.